Flare rates in patients with juvenile idiopathic arthritis (JIA) are high and can be reduced by tapering methotrexate (MTX) first before tumor necrosis factor inhibitors (TNFi), research presented at the 2013 ACR/ARHP Annual Meeting has found.
The safety and efficacy of adalimumab in children 2—4 years of age were comparable to that observed in older children with juvenile idiopathic arthritis (JIA), study authors presented at 2013 ACR/ARHP Annual Meeting.
Current use of postmenopausal hormone therapy was associated with a decreased risk of ACPA-positive—but not ACPA-negative—rheumatoid arthritis, a study presented at the 2013 ACR/ARHP Annual Meeting has shown.
Etanercept is associated with a higher rate of improvement in height z-score over the first 2 years of therapy in patients with juvenile idiopathic arthritis (JIA), according to study results presented at the 2013 ACR/ARHP Annual Meeting.
Early aggressive therapy in a group of patients with polyarticular juvenile idiopathic arthritis (JIA), with high initial disease activity and proportion with RF positivity, was associated with prolonged periods of clinical inactive disease, as presented at the 2013 ACR/ARHP Annual Meeting.
Vitamin D supplementation has a positive effect on global muscle strength; specifically, lower limb muscle strength, a meta-analysis presented at the 2013 ACR/ARHP Annual Meeting has found.
At the 2013 ACR/ARHP Annual Meeting, study investigators presented that etanercept treatment for 96 weeks was well tolerated and effective in pediatric patients with various juvenile idiopathic arthritis subtypes.
Adalimumab appears to be as effective as tocilizumab in treating polyarticular-course juvenile idiopathic arthritis (pcJIA), researchers presented at the 2013 ACR/ARHP Annual Meeting.
